SNY - Sanofi (SNY) Q1 2024 Earnings Call Transcript
2024-04-25 11:24:10 ET
Sanofi (SNY)
Q1 2024 Earnings Conference Call
April 25, 2024 08:30 AM ET
Company Participants
Paul Hudson - Chief Executive Officer
François-Xavier Roger - Chief Financial Officer
Houman Ashrafian - Executive Vice President & Head-Research & Development
Brian Foard - Executive Vice President & Head-Specialty Care, Sanofi
Thomas Triomphe - Executive Vice President-Vaccines, Sanofi
Olivier Charmeil - Executive Vice President-General Medicines, Sanofi
Conference Call Participants
Peter Welford - Jefferies
Luisa Hector - Berenberg
Graham Parry - BofA
Emily Field - Barclays
Emmanuel Papadakis - Deutsche bank
Seamus Fernandez - Guggenheim
Jo Walton - UBS
David Risinger - Leerink
Gary Steventon - Exane
Peter Verdult - Citi
Presentation
Paul Hudson
Welcome to the Q1 2024 conference call. You can find the slides of this call on the sanofi.com Investors Page. I'd like to remind you that the information presented in this call contains forward-looking statements, which is subject to substantial risks and uncertainties that may cause actual results to differ materially. I encourage you to read the disclaimer in our presentation. In addition, I refer you to our Form 20-F on file with the SEC [Foreign Language] for a description of these risk factors.
I'm pleased to welcome our new CFO, François to the presentation, and François will be followed by Houman, our Head of R&D on the pipeline. For Q&A, we have Brian, Olivier, Thomas and Julie to cover the global business units and Roy, our GC.
For the Q&A, you have two options to participate. In Zoom, Raise Your Hand to submit your questions in Q&A. Those have been explained on the slide.
Let's turn to the business. We had an excellent start in 2024 with 7% sales growth, in line with our fast-moving portfolio transformation, growth was driven by launches, including new and existing indications for Dupixent and this performance fully underpins our 2024 EPS guidance as CEO. Dupixent continues to increase penetration in all approved indications, and we saw performance diversified further across all geographies, plus, of course, the usual US insurance plans.
Pharma launches were led by Nexviazyme and Altuviiio with more details to come a little later. Launches also boosted the performance in Vaccines with Beyfortus making further progress including in countries in the southern hemisphere.
In Consumer Health, growth of 9% reflected the consolidation of the Qunol acquisition as well, of course, as organic growth. We're progressing the plan to separate this business as discussed in the past.
Overall, we're pleased with the ongoing portfolio transformation, which is becoming more visible, also in our cost lines with more resources going into the pipeline and less into SG&A. This is exactly the development we set out last year and when we announced the next chapter of our strategy.
Before moving on, I'd like to extend my thanks to all the Sanofi colleagues for their dedicated work and their commitment to patients, of science to improve people's lives. Dupixent continues to perform a strong demand-driven growth. Therein sales of more than €2.8 billion in the first quarter. Sales of this unique medicine increased by 25% globally, fueled by the accelerated growth from indication expansions in the ex U.S. markets, where sales grew as much as 51%.
With now more than 850,000 patients worldwide, the strong contribution from countries like Japan, China and Germany highlights the tremendous growth potential for Dupixent across all indications and geographies.
In the U.S., sales exceeded €2 billion in the quarter, up 17% and as we can see every year, U.S. growth reflects the impact from the customary dynamics of the annual reset of insurance plans. Almost eight years into its initial U.S. launch in atopic dermatitis, this effect underscores the large size and rapid growth of Dupixent with the leadership positions in new prescriptions across all five approved indications....
Sanofi (SNY) Q1 2024 Earnings Call Transcript